CORE--CLINICAL INVESTIGATIONS

UCLA CFAR临床研究核心旨在促进 临床HIV感染与相关恶性肿瘤的相互作用 并发症核心利用主任的专门知识， Kaposi肉瘤的发病机制和基于免疫的治疗，并访问 免疫缺陷患者临床试验产生的临床材料 调节剂，如干扰素、白细胞介素-2、白细胞介素-4和 白细胞介素-12试验。通过促进基本 科学家和临床医生，成本效益和生产力的研究往往 结果.核心提供四项基本服务： 1.为科学家和基础研究人员提供后勤支持， 进一步加深了我们对聚集性血小板减少症免疫发病机制的理解， 来自患者的临床标本，包括血清、血浆、脊髓液和 其他非恶性体液。 2.获取非恶性储存临床标本，包括获取 来自免疫调节剂或基因患者的独特临床标本 回顾性研究的治疗试验。 3.咨询支助，包括协助向 预期标本的机构审查委员会，以及 4.维护现有标本的计算机数据库， 检索 该核心目前有超过40，000个标本可用，并具有相关性。 超过4,000名患者的临床信息。核心继续收购 每年超过1,000个新样本。1996年，8名调查员处理了 从岩芯中采集了5,230个样本。核心提供了大部分的 以再收费方式提供服务，为用户提供核心设施， 最具成本效益的方法存储，处理和检索 储存的标本。希望通过鼓励基础科学家 使用临床材料进行研究，体外观察可以 迅速转化为临床试验，理想的是改善治疗， 艾滋病。该核心不提供临床试验支持。

The UCLA CFAR Clinical Investigations Core is designed to facilitate interactions between clinical HIV infection and its related malignant complications. The core utilizes the expertise of the director in the pathogenesis of Kaposi sarcoma and immune based therapy and accesses the clinical materials generated from clinical trials of patients with immune modulating agents such as interferons, interleukin-2, interleukin-4, and interleukin-12 trials. By facilitating a close interface between basic scientists and clinicians, cost effective and productive studies often result. The core provides four basic services: 1. logistical support for the scientists and basic researchers that further our understanding of the immunopathogenesis of collection of clinical specimens from patients including serum, plasma, spinal fluid and other non-malignant body fluids. 2. access to non-malignant stored clinical specimens including access to unique clinical specimens from patients on immune modulator or gene therapy trials for retrospective studies. 3. consultative support including assistance with applications to the institutional review board for prospective specimens, and 4. maintains a computerize data base of existing specimens for easy retrieval. The core currently has over 40,000 specimens available and has correlative clinical information on over 4,000 patients. The core continues to acquire over 1,000 new samples per year. In 1996, eight investigators processed or obtained 5,230 samples from the core. The core provides the bulk of its services on a re-charge basis providing users with a core facility that is the most cost effective approach for storage, processing and retrieval of stored specimens. It is hoped that by encouraging basic scientists to perform studies using clinical materials, in vitro observations can be rapidly translated into clinical trials and, ideally improved therapy for HIV. This core does not provide clinical trials support.